JP2014503206A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503206A5
JP2014503206A5 JP2013544747A JP2013544747A JP2014503206A5 JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5 JP 2013544747 A JP2013544747 A JP 2013544747A JP 2013544747 A JP2013544747 A JP 2013544747A JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5
Authority
JP
Japan
Prior art keywords
recombinant
adenoviral
adenoviral vector
vector
antigen protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013544747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503206A (ja
JP6054876B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/064944 external-priority patent/WO2012082918A1/en
Publication of JP2014503206A publication Critical patent/JP2014503206A/ja
Publication of JP2014503206A5 publication Critical patent/JP2014503206A5/ja
Application granted granted Critical
Publication of JP6054876B2 publication Critical patent/JP6054876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013544747A 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン Active JP6054876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295410P 2010-12-14 2010-12-14
US61/422,954 2010-12-14
PCT/US2011/064944 WO2012082918A1 (en) 2010-12-14 2011-12-14 Adenovirus serotype 26 and serotype 35 filovirus vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206679A Division JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2014503206A JP2014503206A (ja) 2014-02-13
JP2014503206A5 true JP2014503206A5 (cg-RX-API-DMAC10.html) 2015-01-29
JP6054876B2 JP6054876B2 (ja) 2016-12-27

Family

ID=46245095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013544747A Active JP6054876B2 (ja) 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Country Status (14)

Country Link
US (1) US9701718B2 (cg-RX-API-DMAC10.html)
EP (1) EP2655604B1 (cg-RX-API-DMAC10.html)
JP (2) JP6054876B2 (cg-RX-API-DMAC10.html)
KR (1) KR101879892B1 (cg-RX-API-DMAC10.html)
CN (1) CN103370411B (cg-RX-API-DMAC10.html)
AU (1) AU2011343798B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013014712B1 (cg-RX-API-DMAC10.html)
CA (1) CA2821289C (cg-RX-API-DMAC10.html)
DK (1) DK2655604T3 (cg-RX-API-DMAC10.html)
EA (1) EA029504B1 (cg-RX-API-DMAC10.html)
ES (1) ES2676196T3 (cg-RX-API-DMAC10.html)
PL (1) PL2655604T3 (cg-RX-API-DMAC10.html)
WO (1) WO2012082918A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201304260B (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101879892B1 (ko) 2010-12-14 2018-08-17 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2015311852B2 (en) 2014-09-03 2018-12-13 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
MA40765B1 (fr) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
EP3271729B1 (en) 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
PL3390430T3 (pl) 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
CN108697591B (zh) 2016-02-18 2022-06-17 国际香料和香精公司 聚脲胶囊组合物
EP3429740B1 (en) 2016-03-18 2021-05-05 International Flavors & Fragrances Inc. Silica microcapsules and methods of preparing same
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
CN109414376A (zh) 2016-07-01 2019-03-01 国际香料和香精公司 稳定的微胶囊组合物
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484505A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP4209264A1 (en) 2016-09-16 2023-07-12 International Flavors & Fragrances Inc. Microcapsule compositions stabilized with viscosity control agents
US20180085291A1 (en) 2016-09-28 2018-03-29 International Flavors & Fragrances Inc. Microcapsule compositions containing amino silicone
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
US20180346648A1 (en) 2017-05-30 2018-12-06 International Flavors & Fragrances Inc. Branched polyethyleneimine microcapsules
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019023566A1 (en) * 2017-07-28 2019-01-31 Janssen Vaccines & Prevention B.V. METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
JP2021506300A (ja) 2017-12-19 2021-02-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物
CN112041361B (zh) 2018-04-27 2023-06-30 国际香料和香精公司 稳定的聚脲微胶囊组合物
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
WO2020064621A1 (en) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
BR112021011942A2 (pt) 2018-12-18 2021-09-08 International Flavors & Fragrances Inc. Microcápsula, processo para preparar uma composição de microcápsula, composição de microcápsula, e, produto de consumo
WO2020131879A2 (en) 2018-12-18 2020-06-25 International Flavors & Fragrances Inc. Protein microcapsules and method of preparing the same
WO2020229906A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Efficient impurity removal using a diafiltration process
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
KR20230009445A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나바이러스 스파이크 단백질 융합 단백질
EP4171627A1 (en) 2020-06-29 2023-05-03 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
BR112022026974A2 (pt) 2020-07-06 2023-01-24 Janssen Pharmaceuticals Inc Proteínas de fusão estabilizadas de proteínas de pico de coronavírus
IL299571A (en) 2020-07-08 2023-02-01 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
EP4124383A1 (en) 2021-07-27 2023-02-01 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4154974A1 (en) 2021-09-23 2023-03-29 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
US20260085096A1 (en) 2022-09-23 2026-03-26 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
EP4590690A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
EP4406641A1 (en) 2023-01-26 2024-07-31 International Flavors & Fragrances Inc. Biodegradable microcapsules containing low log p fragrance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852324B1 (en) * 1997-12-23 2005-02-08 The United States Of America As Represented By The Department Of Health And Human Services Immunization for ebola virus infection
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
CA2462455C (en) * 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1553983A2 (en) * 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
AU2004262022B2 (en) * 2003-08-01 2010-10-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Accelerated vaccination
WO2006037038A1 (en) * 2004-09-27 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Optimized vaccines to provide protection against ebola and other viruses
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
CN101072879B (zh) * 2004-10-13 2011-05-11 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用
BRPI0518146A (pt) * 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
KR101879892B1 (ko) 2010-12-14 2018-08-17 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신

Similar Documents

Publication Publication Date Title
Martin et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Fausther-Bovendo et al. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
JP2020528911A5 (cg-RX-API-DMAC10.html)
JP2019530462A5 (cg-RX-API-DMAC10.html)
JP2014502156A5 (cg-RX-API-DMAC10.html)
JP2018520997A5 (cg-RX-API-DMAC10.html)
JP2016510989A5 (cg-RX-API-DMAC10.html)
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
JP2011530309A5 (cg-RX-API-DMAC10.html)
JP2015533841A5 (cg-RX-API-DMAC10.html)
JP2016539946A5 (cg-RX-API-DMAC10.html)
JP2012126742A5 (cg-RX-API-DMAC10.html)
JP2014516536A5 (cg-RX-API-DMAC10.html)
JP2013507907A5 (cg-RX-API-DMAC10.html)
JP2016534034A5 (cg-RX-API-DMAC10.html)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2016513115A5 (cg-RX-API-DMAC10.html)
JP2017528158A5 (cg-RX-API-DMAC10.html)
RU2017113571A (ru) Рекомбинантные вакцины от fmdv и их применение
JP2015057052A5 (cg-RX-API-DMAC10.html)
RU2019107976A (ru) Композиция вакцины
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
JP2016516723A5 (cg-RX-API-DMAC10.html)
JP2015501656A5 (cg-RX-API-DMAC10.html)
JP2011500718A5 (cg-RX-API-DMAC10.html)